Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

AI Is Accelerating Drug Development; But Data Risks Could Break It

BioSpace’s NextGen 2026 biotech leaders highlighted at a recent industry discussion how artificial intelligence is rapidly reshaping drug development while exposing a critical weakness in pharmaceutical innovation: data quality. Executives from emerging biotech companies emphasized that while AI accelerates discovery
  • News
AI Is Accelerating Drug Development; But Data Risks Could Break It

Aragen completes FDA Fast Track mAb scale-up; what enabled this 9-month turnaround

Aragen has completed technology transfer and initiated first commercial-scale GMP manufacturing runs for Renaissance Pharma’s lead monoclonal antibody Daretabart at its Bengaluru facility in India. The company originally developed the cell line and early process at its Morgan Hill site
  • News
Aragen completes FDA Fast Track mAb scale-up; what enabled this 9-month turnaround

Why Inspection Readiness Is Becoming Harder; Digital GMP Raises New Risks

In a recent interview with Christopher Cole of Pharmaceutical Technology, Henrik Johanning from Epista Life Science discussed how pharmaceutical manufacturing and regulatory systems in Europe are shifting from 2025 into 2026. He explained that quality risk management, digital GMP, and
  • News
Why Inspection Readiness Is Becoming Harder; Digital GMP Raises New Risks

FDA Leadership Shakeup Raises Alarm; DTC Drug Ads Face Sudden Enforcement Shift

In September 2025, President Donald Trump called for stricter enforcement of existing rules on direct-to-consumer (DTC) prescription drug advertising by the U.S. Food and Drug Administration (FDA). Around the same period, HHS Secretary Robert F. Kennedy Jr. also criticized pharmaceutical
  • News
FDA Leadership Shakeup Raises Alarm; DTC Drug Ads Face Sudden Enforcement Shift

AI in Clinical Trials Faces Trust Crisis; Regulatory Uncertainty Grows

A recent survey by the Pistoia Alliance at the Clinical Trials Technology Congress (CTTC) in London shows that trust issues and regulatory uncertainty continue to slow artificial intelligence adoption in clinical trials. Although AI already delivers early value in clinical
  • News
AI in Clinical Trials Faces Trust Crisis; Regulatory Uncertainty Grows

FDA Quietly Rewrites Drug Repurposing Rules; Pharma Data Validation Suddenly Becomes Critical

The FDA is urging pharmaceutical companies to re-examine decades of clinical and real-world data using AI and advanced analytics to identify new uses for existing drugs. Published on May 29, 2026, this initiative highlights how legacy datasets may still hold
  • News
FDA Quietly Rewrites Drug Repurposing Rules; Pharma Data Validation Suddenly Becomes Critical

Pharma Goes Digital; GMP Compliance Will Never Be the Same

A major shift is underway in pharmaceutical manufacturing as companies move toward hybrid cloud infrastructure, advanced analytics, and digital quality systems. Speaking on the industry's evolving landscape, Mike Hennessy Jr. of MJH Life Sciences highlighted how hybrid cloud architectures, statistical
  • News
Pharma Goes Digital; GMP Compliance Will Never Be the Same

China Biotech Forces Pharma Power Shift; $10B Pfizer Deal Marks Turning Point

Pfizer’s $10 billion licensing deal with Innovent, alongside rising U.S. debate over expanding COINS Act restrictions on China biotech investment, signals a structural shift in global pharma strategy. The announcement, combined with Astellas’ Xtandi patent cliff response and ASCO scrutiny
  • News
China Biotech Forces Pharma Power Shift; $10B Pfizer Deal Marks Turning Point

Pharma Shifts From Validation to Speed; What Changed Behind It

As development timelines shrink across the pharmaceutical industry, companies are placing greater emphasis on speed, scalability and manufacturing certainty. The trend, highlighted at CPHI Japan 2026, signals mounting pressure on drugmakers and CDMOs to deliver faster without compromising GMP compliance,
  • News
Pharma Shifts From Validation to Speed; What Changed Behind It

FDA One-Day Inspections Trigger Compliance Shock; AI Shift Reshapes Global Pharma Oversight

FDA launches one-day inspections and expands AI systems Elsa 4.0 and HALO at its headquarters in the United States, introducing a major shift in global pharmaceutical regulation. The move accelerates risk-based oversight and structured-data review, reshaping GMP expectations for manufacturers
  • News
FDA One-Day Inspections Trigger Compliance Shock; AI Shift Reshapes Global Pharma Oversight